Serological tests are crucial in a pandemic scenario, since they are a valuable tool to spot those citizens with potential immunity, specific regions with herd immunity or particular at-risk populations, as well as acquired immunity after vaccination. Hence, high-throughput, fast, cost-effective, and straightforward technologies facilitating interrogation of COVID-19 seroconversion are an existing need. Herein, we developed an innovative assay for the determination of COVID-19 seroconversion. Fluorophore-labeled SARS-CoV-2 spike receptor-binding domain recombinant protein (F-RBD) was discovered to operate as a bioprobe that emits a strong fluorescence upon COVID-19 antibody detection; however, F-RBD fluorescence was deactivated by graphene oxide-decorated surfaces when COVID-19 antibodies are absent in the sample. With a cost of less than 0.5 USD per test (at laboratory scale), the biosensing system offers optimum results within 42 min. To demonstrate that this technology is technically sound in a relevant environment, 34 human serum samples were analyzed and clearly differentiated, requiring a tiny amount of serum (1 μL to be later diluted in saline buffer).
Keywords: 2D materials; biophotonics; infectious diseases; pathogens; photoluminescent probe.